[
  {
    "ts": null,
    "headline": "Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients",
    "summary": "On Tuesday, Merck & Co Inc (NYSE:MRK) revealed topline results from the pivotal Phase 3 MK-3475A-D77 trial evaluating the noninferiority of subcutaneous administration of pembrolizumab together with berahyaluronidase alfa, administered with chemotherapy versus intravenous (IV) Keytruda administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Pembrolizumab is available for intravenous use as Keytruda, Berahyaluronidase alfa",
    "url": "https://finnhub.io/api/news?id=0160108fc8a2fb641bba01549252d63a343b3f5831733b075436ec9e015b9629",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732040255,
      "headline": "Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients",
      "id": 131484824,
      "image": "https://media.zenfs.com/en/Benzinga/183302d26928f4365cfdeaaff3aae0e5",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "On Tuesday, Merck & Co Inc (NYSE:MRK) revealed topline results from the pivotal Phase 3 MK-3475A-D77 trial evaluating the noninferiority of subcutaneous administration of pembrolizumab together with berahyaluronidase alfa, administered with chemotherapy versus intravenous (IV) Keytruda administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Pembrolizumab is available for intravenous use as Keytruda, Berahyaluronidase alfa",
      "url": "https://finnhub.io/api/news?id=0160108fc8a2fb641bba01549252d63a343b3f5831733b075436ec9e015b9629"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces First-Quarter 2025 Dividend",
    "summary": "RAHWAY, N.J., November 19, 2024--Merck Announces First-Quarter 2025 Dividend",
    "url": "https://finnhub.io/api/news?id=8a602d5ce962627cda2e55174302a3c8fefd99bbbcf76f75847665108d56f961",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732036920,
      "headline": "Merck Announces First-Quarter 2025 Dividend",
      "id": 131484826,
      "image": "https://media.zenfs.com/en/business-wire.com/71e50502ccf863e6b573fec3826a5238",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 19, 2024--Merck Announces First-Quarter 2025 Dividend",
      "url": "https://finnhub.io/api/news?id=8a602d5ce962627cda2e55174302a3c8fefd99bbbcf76f75847665108d56f961"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=cfbe1049092fbfa9d502b8f6432c3b5c03ba99d0a0f6321a7896b8a90282d5ad",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732034100,
      "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "id": 131506353,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=cfbe1049092fbfa9d502b8f6432c3b5c03ba99d0a0f6321a7896b8a90282d5ad"
    }
  },
  {
    "ts": null,
    "headline": "Inhibikase: Potential To Improve Current Treatment Options For PAH Patients",
    "summary": "News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding. Click here to read my analysis.",
    "url": "https://finnhub.io/api/news?id=0f93af4eab00cd121d892a49efd933891fd9e0aa5df8df4612f83dbdbdac90d5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732023155,
      "headline": "Inhibikase: Potential To Improve Current Treatment Options For PAH Patients",
      "id": 131482239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2168077727/image_2168077727.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding. Click here to read my analysis.",
      "url": "https://finnhub.io/api/news?id=0f93af4eab00cd121d892a49efd933891fd9e0aa5df8df4612f83dbdbdac90d5"
    }
  },
  {
    "ts": null,
    "headline": "Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)",
    "summary": "SPDRÂ® S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.",
    "url": "https://finnhub.io/api/news?id=109ddd120641122e255332ba00679b7b978c2e03ced531275de667fe4d7d4cd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732021874,
      "headline": "Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)",
      "id": 131480822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "SPDRÂ® S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.",
      "url": "https://finnhub.io/api/news?id=109ddd120641122e255332ba00679b7b978c2e03ced531275de667fe4d7d4cd2"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Raises Quarterly Dividend by 5.2%",
    "summary": "By Colin Kellaher Merck & Co.'s board has raised the drugmaker's quarterly dividend by 5.2%, to 81 cents a share from 77 cents. The new payout, equal to $3.24 a year, represents an annual...",
    "url": "https://finnhub.io/api/news?id=51501bfb7bf5c64a48b3ae0986d529c9112d4d3a342bad69e220f21015cd24ff",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732020429,
      "headline": "Merck & Co. Raises Quarterly Dividend by 5.2%",
      "id": 131478961,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co.'s board has raised the drugmaker's quarterly dividend by 5.2%, to 81 cents a share from 77 cents. The new payout, equal to $3.24 a year, represents an annual...",
      "url": "https://finnhub.io/api/news?id=51501bfb7bf5c64a48b3ae0986d529c9112d4d3a342bad69e220f21015cd24ff"
    }
  },
  {
    "ts": null,
    "headline": "How I Repurposed My Late Father's Trust Account",
    "summary": "I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.",
    "url": "https://finnhub.io/api/news?id=15b16fcae92f6698a79d30b640741803fef606dc53bf6706d6ae2323f9f9d2f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732019685,
      "headline": "How I Repurposed My Late Father's Trust Account",
      "id": 131478623,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/175431947/image_175431947.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.",
      "url": "https://finnhub.io/api/news?id=15b16fcae92f6698a79d30b640741803fef606dc53bf6706d6ae2323f9f9d2f9"
    }
  },
  {
    "ts": null,
    "headline": "Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says",
    "summary": "Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous form of its cancer drug.",
    "url": "https://finnhub.io/api/news?id=8bba8dfe8f7fc024cfe0fff9154a0e7c8d0a8ff5e93a1bdf6ac43393aba2b9fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732016820,
      "headline": "Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says",
      "id": 131484828,
      "image": "https://imgproxy.divecdn.com/AlXLoSw20uf2IU4hAJGBerY7Pha_obEiMpjvjE1bSQo/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL1NjcmVlbnNob3RfMjAyMi0wNy0yNF8xLjQyLjM3X1BNLnBuZw==.webp",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous form of its cancer drug.",
      "url": "https://finnhub.io/api/news?id=8bba8dfe8f7fc024cfe0fff9154a0e7c8d0a8ff5e93a1bdf6ac43393aba2b9fd"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints",
    "summary": "RAHWAY, N.J., November 19, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA®, together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; \"subcutaneous pembrolizumab\"",
    "url": "https://finnhub.io/api/news?id=498e14ee89e3e6343695fe8ceb6ae2c6eb456b5c736a6539e37cfc6562f2ab9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732016700,
      "headline": "Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints",
      "id": 131471590,
      "image": "https://media.zenfs.com/en/business-wire.com/de3ca49c01c5305c37dde0ea343c2886",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 19, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA®, together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; \"subcutaneous pembrolizumab\"",
      "url": "https://finnhub.io/api/news?id=498e14ee89e3e6343695fe8ceb6ae2c6eb456b5c736a6539e37cfc6562f2ab9f"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
    "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
    "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732015683,
      "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
      "id": 131474886,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429734/image_107429734.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
      "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.",
    "summary": "Merck’s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.",
    "url": "https://finnhub.io/api/news?id=40a3219469e4f6693c7cd1bbbdc4c0a187c63bc877ee3de409d59a788161700b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732013340,
      "headline": "Merck’s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.",
      "id": 131473534,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck’s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.",
      "url": "https://finnhub.io/api/news?id=40a3219469e4f6693c7cd1bbbdc4c0a187c63bc877ee3de409d59a788161700b"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For November",
    "summary": "November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.",
    "url": "https://finnhub.io/api/news?id=17b2ae374f72b898be1e13a220d648b578b5b9ae1db05e9f4365ec93e3d05504",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732007700,
      "headline": "IXJ: Healthcare Sector Dashboard For November",
      "id": 131471159,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/688000635/image_688000635.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.",
      "url": "https://finnhub.io/api/news?id=17b2ae374f72b898be1e13a220d648b578b5b9ae1db05e9f4365ec93e3d05504"
    }
  },
  {
    "ts": null,
    "headline": "Merck: success of a subcutaneous version of Keytruda",
    "summary": "On Tuesday, Merck announced the success of a Phase III trial involving subcutaneous administration of its flagship immunotherapy Keytrud, in the treatment of a form of bronchial cancer.The study,...",
    "url": "https://finnhub.io/api/news?id=6e58e50e79487a6158826f3ed374cacb7851957860038edbf562406a885c63f6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732005319,
      "headline": "Merck: success of a subcutaneous version of Keytruda",
      "id": 131470299,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "On Tuesday, Merck announced the success of a Phase III trial involving subcutaneous administration of its flagship immunotherapy Keytrud, in the treatment of a form of bronchial cancer.The study,...",
      "url": "https://finnhub.io/api/news?id=6e58e50e79487a6158826f3ed374cacb7851957860038edbf562406a885c63f6"
    }
  },
  {
    "ts": null,
    "headline": "Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation",
    "summary": "Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation",
    "url": "https://finnhub.io/api/news?id=245f551443cafdf38622151db32d653f4a1897fad4d487a776c8c92b74388230",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732002840,
      "headline": "Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation",
      "id": 131473536,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation",
      "url": "https://finnhub.io/api/news?id=245f551443cafdf38622151db32d653f4a1897fad4d487a776c8c92b74388230"
    }
  }
]